4,4-dimethylcholesta-8,14,24-trien-3β-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4,4-dimethylcholesta-8,14,24-trien-3β-ol
• 英文别名: 4,4-Dimethylcholesta-8(9),14,24-trien-3beta-ol；(3S,10S,13R,17R)-4,4,10,13-tetramethyl-17-[(2R)-6-methylhept-5-en-2-yl]-1,2,3,5,6,7,11,12,16,17-decahydrocyclopenta[a]phenanthren-3-ol
• 化学式: C₂₉H₄₆O
• 分子量: 410.684
• InChiKey: LFQXEZVYNCBVDO-ZKRAVAGISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Meiosis regulating compounds
  申请人：——

  公开号：US20020013302A1

  公开（公告）日：2002-01-31

  Sterol derivative compounds, structurally related to natural compounds which can be extracted from bull testes and from human follicular fluid, useful for regulating meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives.

  甾醇衍生物化合物，结构上与可以从公牛睾丸和人类卵泡液中提取的天然化合物相关，对调节卵母细胞和男性生殖细胞中的减数分裂有用。其中一些化合物对治疗不孕症有用，而其他化合物则可用作避孕药。
• Regulation of meiosis
  申请人：Byskov Grete Anne

  公开号：US20050222098A1

  公开（公告）日：2005-10-06

  Compounds of Formula I and methods of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of the compound of Formula I to a germ cell in need of such a treatment.

  公式I的化合物及调节哺乳动物生殖细胞减数分裂的方法，该方法包括向需要此类治疗的生殖细胞中施用公式I的化合物的有效量。
• COMPOUNDS AND METHODS OF PROMOTING MYELINATION
  申请人：Case Western Reserve University

  公开号：EP3838287A2

  公开（公告）日：2021-06-23

  A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

  一种通过提高少突胶质细胞前体细胞的存活率和/或成熟度来促进少突胶质细胞生成的方法，包括向细胞施用有效量的制剂，该制剂可提高和/或诱导胆固醇生物合成途径的Δ8,9-不饱和固醇中间体在少突胶质细胞前体细胞中的积累。
• Compositions for the treatment of cataracts
  申请人：Catacore, Inc.

  公开号：US10398709B2

  公开（公告）日：2019-09-03

  In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.

  在一个实施方案中，本申请公开了一种用于治疗眼部疾病、病变和损伤的水性眼科组合物，该组合物包括a) 一种类固醇，或至少两种类固醇的组合，选自由羊毛甾醇、二氢羊毛甾醇、4,4-二甲基胆甾-8(9),14,24-三烯-3β-醇、4,4-二甲基胆甾-8,24-二烯-3β-醇、4,4-二甲基胆甾-8-烯-3β-醇组成的组、4,4-二甲基胆甾烯-8(9),14-二烯-3β-醇、14-去甲基羊毛甾醇、羊毛甾醇、Δ7,24-胆甾烯醇、胆固醇、胆甾-7-烯醇、胆固醇酯、7-脱氢胆固醇、去甾醇、7-脱氢去甾醇、去甾醇、27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate. 25-ol), 5-cholesten-3β-Sulfate、25-醇）、5-胆甾烯-3β,25-二醇、二硫酸盐和它们的酯，或它们的药学上可接受的盐，其浓度对治疗和/或预防眼病、病变和损伤有效；b) 药用辅料；以及使用此类组合物的治疗方法。
• Methods and compositions for treating drug resistance in cancer
  申请人：UNIVERSITY OF SOUTH FLORIDA

  公开号：US10813935B2

  公开（公告）日：2020-10-27

  Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.

  本文公开了用于治疗癌症的组合物和方法。本文还提供了用于减少、抑制或预防癌症对酪氨酸激酶抑制剂的抗药性的组合物和方法。这些方法可包括向受试者施用抗耐药性制剂，如 CYP51A1 抑制剂或 miRNA-764 （SEQ ID NO: 4）的激动剂。除抗耐药性制剂外，还可向受试者施用酪氨酸激酶抑制剂。